Suppr超能文献

绝经后女性中高密度脂蛋白亚类、脂蛋白(A-I)和脂蛋白(A-I:A-II)水平以及脂解酶活性对连续口服雌激素-孕激素和经皮雌激素联合周期性孕激素治疗方案的反应。

Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.

作者信息

Tilly-Kiesi M, Kahri J, Pyörälä T, Puolakka J, Luotola H, Lappi M, Lahdenperä S, Taskinen M R

机构信息

Department of Medicine, Helsinki University Central Hospital, Finland.

出版信息

Atherosclerosis. 1997 Mar 21;129(2):249-59. doi: 10.1016/s0021-9150(96)06036-4.

Abstract

Seventy postmenopausal women took part in the study. Subjects received either continuous oral 17 beta-estradiol 2 mg/day combined with norethisterone acetate 1 mg/day (E2/NETA, Kliogest) or transdermal treatment consisting of 28 day cycles with patches delivering 17 beta-estradiol 50 micrograms/day (Estraderm) combined with cyclic medroxyprogesterone acetate 10 mg/day (E2/MPA, Provera), on days 17-28. At baseline the serum lipid and lipoprotein concentrations, composition and concentrations of high density lipoprotein (HDL) subclasses, lipoprotein (Lp)(AI) and Lp(A-I:A-II) levels were comparable in the two groups. In the E2/NETA group, after 12 months hormone replacement therapy (HRT), the HDL2 cholesterol concentration decreased by 17% (P < 0.01) and the HDL3 cholesterol remained unchanged. The concentrations of HDL2b, HDL2a and HDL3a were reduced by 30, 26 and 15%, respectively, P < 0.001, and the cholesterol:triglyceride ratio decreased significantly in all HDL subclasses. Apolipoprotein (apo) A-I concentration decreased by 5% (P < 0.05), but apo A-II, Lp(A-I) and Lp(A-I:A-II) concentrations remained unchanged. In the E2/MPA group the HDL2 and HDL3 cholesterol levels were both reduced by 6% (P < 0.05) and the HDL3a, HDL3b and HDL3c concentrations decreased by 14, 12 and 17% during the E2/MPA phase compared with baseline (P < 0.01). No major changes in the composition of HDL subclasses occurred in the E2 MPA group during treatment. The apo A-I and Lp(A-I) levels were not changed, but apo A-II and Lp(A-I:A-II) concentrations decreased by 8 and 5%, P < 0.001 and P < 0.05, respectively. At 12 months the postheparin plasma hepatic lipase (HL) activity decreased only in the E2/NETA group (by 12%, P < 0.05). The cholesteryl ester transfer protein (CETP) activity was not affected by either HRT regimen. The results of our study show that the 2 HRT regimens have multiple effects on HDL particles and HRT induced changes in HDL are not associated with changes in activities of lipolytic enzymes or CETP.

摘要

70名绝经后女性参与了这项研究。受试者接受以下两种治疗之一:持续口服17β-雌二醇2毫克/天联合醋酸炔诺酮1毫克/天(E2/NETA,Kliogest);或经皮治疗,即使用每28天为一个周期的贴片,每天释放17β-雌二醇50微克(Estraderm),并在第17 - 28天联合使用醋酸甲羟孕酮10毫克/天(E2/MPA,Provera)。在基线时,两组的血清脂质和脂蛋白浓度、高密度脂蛋白(HDL)亚类的组成和浓度、脂蛋白(Lp)(AI)以及Lp(A - I:A - II)水平相当。在E2/NETA组中,经过12个月的激素替代疗法(HRT)后,HDL2胆固醇浓度下降了17%(P < 0.01),而HDL3胆固醇保持不变。HDL2b、HDL2a和HDL3a的浓度分别降低了30%、26%和15%,P < 0.001,并且所有HDL亚类中的胆固醇与甘油三酯比值均显著下降。载脂蛋白(apo)A - I浓度下降了5%(P < 0.05),但apo A - II、Lp(A - I)和Lp(A - I:A - II)浓度保持不变。在E2/MPA组中,HDL2和HDL3胆固醇水平均下降了6%(P < 0.05),并且与基线相比,在E2/MPA阶段HDL3a、HDL3b和HDL3c浓度分别下降了14%、12%和17%(P < 0.01)。在治疗期间,E2 MPA组中HDL亚类的组成未发生重大变化。apo A - I和Lp(A - I)水平未改变,但apo A - II和Lp(A - I:A - II)浓度分别下降了8%和5%,P < 0.001和P < 0.05。在12个月时,仅E2/NETA组的肝素后血浆肝脂酶(HL)活性下降(下降12%,P < 0.05)。两种HRT方案均未影响胆固醇酯转运蛋白(CETP)的活性。我们的研究结果表明,这两种HRT方案对HDL颗粒有多种影响,并且HRT诱导的HDL变化与脂解酶或CETP活性的变化无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验